Mitral valve replacement with dura mater bioprostheses.
Dura mater bioprostheses for cardiac valve replacement were first introduced in Brazil. They have been used since 1975 at the National Heart Hospital, London, as a mitral valve replacement instead of fascia lata valves or inverted aortic homograft valves. During this period 120 patients have had dura mater valves inserted in the mitral position; 29 also received an aortic valve replacement, 6 with dura mater, 20 with an aortic homograft, 2 with an aortic xenograft and 1 with a prosthetic valve. Perivalvular leaks occurred with seven of these mitral valves, and another seven presented with detached cusps. All but one of these 14 valves were replaced. Emboli have occurred in four of the patients, one of whom died after 35 months with thrombus on the aortic valve, but with an unaffected mitral valve. There were 15 early deaths, a hospital mortality of 12.5%, and 10 late deaths, a postoperative mortality of 9.5%. Actuarial analysis has shown a four-year postoperative survival of 78.9%.
D001021:Aortic Valve; D001705:Bioprosthesis / Q000009:adverse effects; D004388:Dura Mater; D006350:Heart Valve Prosthesis / Q000009:adverse effects; D006801:Humans; D008943:Mitral Valve; D011183:Postoperative Complications; D011379:Prognosis; D011474:Prosthesis Design; D014184:Transplantation, Homologous